Skip to main content

Table 1 Baseline characteristics of the study population

From: Effects of tourniquet use on clinical outcomes and cement penetration in TKA when tranexamic acid administrated: a randomized controlled trial

Variable Group A
(Tourniquet group)
(N = 50)
Group B
(Non-tourniquet group)
(N = 50)
Group C
(Tourniquet in cementation group)
(N = 50)
p value*
Demographic characteristics
 Age (yr) 68.44 ± 6.80 68.00 ± 7.11 68.66 ± 7.27 0.89
 Male sex (%) 7 (14%) 8 (16%) 7 (14%)
 Weight (kg) 64.39 ± 8.16 62.66 ± 10.44 63.64 ± 11.27 0.67
 Height (cm) 153.88 ± 21.49 157.06 ± 6.74 156.52 ± 7.08 0.46
 BMI (kg/m2) 26.13 ± 2.63 25.34 ± 3.61 25.88 ± 3.51 0.42
 ASA status I-II/≥III
(No. of patients)
35/15 38/12 36/14
Diagnosis
 Primary OA 50 50 50
Preoperative laboratory values
 Preo. Hemoglobin (g/dl) 134.84 ± 12.25 132.18 ± 15.10 129.50 ± 14.98 0.17
 Preo. Hematocrit (L/L) 0.41 ± 0.04 0.41 ± 0.04 0.40 ± 0.04 0.82
 Preo. CRP (109/L) 3.94 ± 3.13 3.29 ± 2.00 3.79 ± 2.30 0.41
 Preo. ESR (mm/L) 21.88 ± 12.59 24.08 ± 13.21 28.32 ± 16.87 0.08
 Preo. IL-6 (pg/ml) 4.28 ± 2.04 3.40 ± 2.19 3.76 ± 2.27 0.13
 Preo. CK (IU/L) 81.52 ± 29.89 85.02 ± 39.71 74.06 ± 31.36 0.26
Preoperative knee function
 VAS score (points) 7.28 ± 0.97 7.32 ± 0.95 7.16 ± 0.87 0.67
Range of motion 94 ± 16 97 ± 20 95 ± 14 0.67
 HHS score (points) 56.64 ± 4.24 55.10 ± 4.62 56.74 ± 4.04 0.11
  1. Abbreviations: OA, osteoarthritis; CRP, C-reaction protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin-6; CK, creatine kinase; HSS score, hospital of special surgery score
  2. *The p value represents the result of one-way analysis of variance for independent means for continuous variables or the chi-square test for independent proportions that included the three groups